Introduction: The Urgent Mandate of METAvivor
In the landscape of oncology, metastatic breast cancer (MBC)—cancer that has spread beyond the breast to bones, liver, lungs, or brain—remains the most critical challenge. Despite the proliferation of awareness campaigns, the vast majority of research funding historically targets early-stage prevention rather than the treatment of stage IV disease. At the center of this struggle is METAvivor, a non-profit organization uniquely dedicated to the specific funding of metastasis research.
In a recent communication, Dr. Kelly Shanahan, President of METAvivor and a physician living with MBC, outlined the current state of the field. Her report details a period of intense activity, marked by a surge in research interest, high-stakes international conferences, and a shifting regulatory environment. As the organization navigates a doubling of grant applications amidst federal funding uncertainty, the focus remains clear: elevating the patient voice to redefine how clinical success is measured.
Main Facts: A Surge in Research Interest and Advocacy
The spring and summer of the current year have proven to be a pivotal juncture for METAvivor. The organization’s Scientific Advisory Board (SAB) recently convened to review 200 Letters of Intent (LOIs) for the current grant cycle. This figure represents a 100% increase over traditional application volumes for the second consecutive year.
According to Dr. Stuart Martin, a long-standing member of the SAB, this influx is not merely a sign of increased scientific interest but a reflection of a broader "challenging time for research." As federal dollars become more precarious and competitive, private organizations like METAvivor are filling a critical vacuum, ensuring that high-impact metastasis research does not stall.
The organization’s leadership is also taking a prominent role on the global stage. Dr. Shanahan has been invited to present at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, as well as the Hormel Institute’s Global Cancer Consortium in Minnesota. These appearances signal a growing recognition within the medical community that patient advocates—particularly those who are also medical professionals—are essential stakeholders in the design of clinical trials.
Chronology of Events: From Grant Reviews to Global Stages
Late May: The Grant Review Process
The cycle began with the SAB meeting to filter the 200 LOIs. The next phase involves inviting the most promising researchers to submit full applications. These proposals will undergo a rigorous double-review process involving both scientific experts and Patient Advocate Reviewers (PARs). This dual-layered approach ensures that funded projects are not only scientifically sound but also relevant to the lived experiences and priorities of the MBC community.
May 31: ASCO and the Call for Meaningful Endpoints
At the ASCO conference in Chicago, one of the world’s largest gatherings of oncology professionals, Dr. Shanahan is scheduled to address a session titled "Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials."
Her presentation focuses on a critical flaw in traditional oncology research: the disconnect between what researchers measure and what patients value. While clinical trials often focus on "Progression-Free Survival" (PFS) or "Overall Survival" (OS), Dr. Shanahan argues for a more nuanced approach that includes quality-of-life metrics and endpoints that reflect the daily reality of living with a chronic, terminal illness.
Mid-June: The Hormel Institute Global Cancer Consortium
Following ASCO, the focus shifts to Minnesota for the Hormel Institute’s symposium. Here, the emphasis will be on the "hallmarks of metastasis." Dr. Danny Welch, a pioneer in the field and an original METAvivor grant recipient, will deliver the keynote. The meeting serves as a technical deep-dive into the biological mechanisms that allow cancer cells to migrate and colonize distant organs, a process that remains the primary cause of breast cancer mortality.
Supporting Data: The Science of New Therapeutics
The field of MBC treatment is currently experiencing a rapid influx of new therapeutic options, particularly for Estrogen Receptor-positive (ER+), HER2-negative (HER2-) subtypes.
The ESR1 Mutation Challenge
A significant portion of current research focuses on the ESR1 mutation, which often develops as a resistance mechanism to aromatase inhibitors (AIs). Data from the SERENA-6 trial has been a focal point of recent discussion. The trial investigated the use of camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), in combination with CDK4/6 inhibitors.
Recent FDA Approvals
The FDA has been active in the second quarter of the year, granting several key approvals:
- Vepdegestrant (Veppanu): A new targeted therapy for ER+/HER2- MBC patients harboring the ESR1 mutation.
- Datopotamab Deruxtecan (Datroway/Dato-DXd): Approved as a first-line treatment for patients with metastatic Triple-Negative Breast Cancer (TNBC) who are ineligible for immunotherapy. This represents a significant advancement for one of the most aggressive forms of the disease.
- Trastuzumab Deruxtecan (Enhertu/TDXd): While already a staple in metastatic care, the FDA expanded its indications into the early-stage HER2+ setting, aiming to reduce the risk of recurrence and the subsequent development of metastatic disease.
Official Responses: Regulatory Divergence and the "Patient Voice"
A major point of contention in the oncology community involves the recent vote by the FDA’s Oncologic Drugs Advisory Committee (ODAC) regarding camizestrant. The committee voted against recommending the approval of switching to camizestrant upon the detection of an ESR1 mutation before radiographic evidence of progression.
The ODAC’s cautious stance contrasts sharply with the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use, which recommended approval based on the same SERENA-6 data. This divergence highlights a fundamental debate in modern oncology: Should treatment be altered based on circulating tumor DNA (ctDNA) and molecular markers, or should clinicians wait for traditional imaging (CT/PET scans) to show physical tumor growth?
METAvivor leadership, including board members Janice Cowden and Lynda Weatherby, has been vocal in this debate. Through the "Live from Stage 4" podcast, they have advocated for the incorporation of new technology into regulatory decisions. The FDA has since announced it is continuing to review the data, leaving the door open for a potential reversal or a more specific indication for the drug.
Implications: Redefining the "Bigger Table"
The surge in grant applications and the prominence of patient advocates at conferences like ASCO suggest a paradigm shift in the oncology world. The implications of this shift are three-fold:
1. The Democratization of Research Funding
The doubling of grant LOIs indicates that the scientific community is increasingly looking toward specialized non-profits to sustain innovation. As federal funding becomes more volatile, the role of community-funded research becomes a pillar of the scientific ecosystem. However, this places a significant burden on fundraising efforts, as the demand for research dollars currently outstrips available resources.
2. The Integration of "Patient-Centered Endpoints"
Dr. Shanahan’s advocacy for trial endpoints that "ask us what we want" is more than a rhetorical flourish. It is a call for a structural change in how the FDA and pharmaceutical companies design studies. If a drug extends life by three months but results in a total loss of functional independence, is it a "success"? By centering the patient voice, the industry is being pushed to value "Time Without Symptoms or Toxicity" (TWiST) alongside traditional survival metrics.
3. The Personalization of Metastatic Care
The approvals of Dato-DXd and vepdegestrant, alongside the debate over ESR1 mutations, underscore the move toward highly personalized medicine. The "one size fits all" approach to breast cancer is being replaced by molecularly driven strategies. For the patient, this means more options, but it also requires a higher level of health literacy and access to advanced diagnostic testing, such as liquid biopsies.
Conclusion: The Reality of Living on the Edge
Behind the statistics, regulatory votes, and scientific symposia lies the human reality of metastatic disease. Dr. Shanahan’s report concludes with a poignant reminder of the stakes: she herself is a participant in a clinical trial, moving directly from the podium at ASCO to a scanning center in Nashville.
For the thousands of individuals living with MBC, the work of METAvivor is not an academic exercise; it is a race against time. The current momentum in research and the emergence of new therapeutics offer a glimmer of hope, but the message from the organization’s leadership remains urgent. To truly move the needle, the medical establishment must not only fund the science but also "pull up a seat" for the patients who are the ultimate experts in the disease.
As the summer progresses, the community awaits the full results of the ASCO presentations and the finalization of the METAvivor grant awards, both of which will shape the trajectory of metastasis research for years to come.
About the Author
